Denmark vs Trinidad and Tobago: Prevalence rate of hypertension in men aged 30-79
Denmark
43.3
in 2019
Trinidad and Tobago
43.2
in 2019
Denmark rank
49th
Trinidad and Tobago rank
50th
Prevalence rate of hypertension in men aged 30-79 over time
- Denmark
- Trinidad and Tobago
How they compare
Denmark currently reports 43.3 against 43.2 in Trinidad and Tobago, a difference of 0.1.
Across all 30 years both countries report, Denmark has been ahead every year.
Denmark ranks 49th and Trinidad and Tobago ranks 50th of 195 countries.
Denmark has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Denmark | Trinidad and Tobago | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 45.59 | 38.53 | 7.06 | Denmark |
| 2000s | 48.18 | 41.32 | 6.86 | Denmark |
| 2010s | 45.79 | 42.96 | 2.83 | Denmark |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence rate of hypertension in men aged 30-79, Denmark or Trinidad and Tobago?
- Denmark, at 43.3 against 43.2 in Trinidad and Tobago as of 2019.
- What is the difference in prevalence rate of hypertension in men aged 30-79 between Denmark and Trinidad and Tobago?
- 0.1, with Denmark ahead.
- How many years of comparable data are there for Denmark and Trinidad and Tobago?
- 30 years are reported by both, from 1990 to 2019.
- How do Denmark and Trinidad and Tobago rank globally for prevalence rate of hypertension in men aged 30-79?
- Denmark ranks 49th and Trinidad and Tobago ranks 50th of 195 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Prevalence rate of hypertension in men aged 30-79. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated share of male population with hypertension, based on population representative surveys and statistical modeling. Hypertension is a risk factor for chronic complications, including cardiovascular disease, and premature death.